{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:35:49Z","timestamp":1765456549370,"version":"3.46.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115695","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:24:19Z","timestamp":1760804659000},"page":"115695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new T cell therapy method for cancer: polyclonal effector tumor antigen-specific T cells isolated from autologous blood or lymph nodes by nanoparticles loading whole tumor antigens"],"prefix":"10.1016","volume":"167","author":[{"given":"Mingze","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115695_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2159-8290.CD-RW2020-160","article-title":"Approach enables isolation of tumor-specific antigen-reactive T cells","volume":"11","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115695_bb0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0264-410X(02)00598-4","article-title":"Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects","volume":"21","author":"Kalos","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2025.115695_bb0015","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/ijc.25601","article-title":"Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation","volume":"128","author":"Widenmeyer","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115695_bb0020","doi-asserted-by":"crossref","unstructured":"Pauken, K.E. & Wherry, E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265\u2013276.","DOI":"10.1016\/j.it.2015.02.008"},{"key":"10.1016\/j.intimp.2025.115695_bb0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115695_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-96376-7_4","article-title":"Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer","volume":"183","author":"Molvi","year":"2022","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/2326-6066.CIR-17-0519","article-title":"High-dimensional profiling of tumor-specific immune responses: asking T cells about what they \u201csee\u201d in cancer","volume":"6","author":"Newell","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0040","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.juro.2011.11.083","article-title":"Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer","volume":"187","author":"Hadaschik","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2025.115695_bb0045","doi-asserted-by":"crossref","first-page":"20884","DOI":"10.1073\/pnas.0710557105","article-title":"Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma","volume":"104","author":"Vence","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2025.115695_bb0050","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.micinf.2005.03.028","article-title":"Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy","volume":"7","author":"Wang","year":"2005","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2025.115695_bb0055","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.4049\/jimmunol.0903612","article-title":"Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire","volume":"184","author":"Fourcade","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115695_bb0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/imt-2017-0130","article-title":"Cancer immunotherapy using tumor antigen-reactive T cells","volume":"10","author":"Choi","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2025.115695_bb0065","first-page":"1057","article-title":"Suppression of tumor antigen-specific T cell immune responses by regulatory T cells","volume":"41","author":"Shimazu","year":"2014","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.intimp.2025.115695_bb0070","first-page":"3311","article-title":"Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma","volume":"119","author":"Bonertz","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115695_bb0075","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77274","article-title":"Pinpointing the tumor-specific T cells via TCR clusters","volume":"11","author":"Goncharov","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.intimp.2025.115695_bb0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0085","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2025.115695_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.blre.2005.05.001","article-title":"Generation of tumor-specific T-cell therapies","volume":"20","author":"Morris","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.intimp.2025.115695_bb0095","first-page":"1677","article-title":"Mass-production of tumor antigen-specific cytotoxic T lymphocytes using the iPS cell technology-development of \u201coff-the-shelf T cells\u201dfor the use in allogeneic transfusion settings","volume":"46","author":"Kawamoto","year":"2019","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.intimp.2025.115695_bb0100","doi-asserted-by":"crossref","unstructured":"Gubin, M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutan T antigens. Nature 515, 577\u2013581.","DOI":"10.1038\/nature13988"},{"key":"10.1016\/j.intimp.2025.115695_bb0105","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115695_bb0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-4939-9794-7_12","article-title":"Detection of tumor antigen-specific T-cell responses after oncolytic vaccination","volume":"2058","author":"Pol","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115695_bb0115","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/1078-0432.CCR-18-1356","article-title":"High-throughput screening of human tumor antigen-specific CD4 T cells, including neoantigen-reactive T cells","volume":"25","author":"Costa-Nunes","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0120","doi-asserted-by":"crossref","first-page":"19056","DOI":"10.1021\/acs.analchem.4c04049","article-title":"Efficient biomarker for immunotherapy: measuring broad clones effector tumor antigen-specific T cells in the blood of esophageal cancer patients","volume":"96","author":"Wang","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2025.115695_bb0125","article-title":"Efficient predictor for immunotherapy efficacy: detecting pan-clones effector tumor antigen-specific T cells in blood by nanoparticles loading whole tumor antigens","volume":"12","author":"Zeng","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.intimp.2025.115695_bb0130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2025.115695_bb0135","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/acs.analchem.1c03678","article-title":"High-throughput functional screening of antigen-specific T cells based on droplet microfluidics at a single-cell level","volume":"94","author":"Wang","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.intimp.2025.115695_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40425-018-0467-y","article-title":"A rare population of tumor antigen-specific CD4(+)CD8(+) double-positive alphabeta T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells","volume":"7","author":"Matsuzaki","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.115695_bb0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115695_bb0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.115695_bb0155","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115695_bb0160","doi-asserted-by":"crossref","unstructured":"Reck, M., Remon, J. & Hellmann, M.D. First-line immunotherapy for non-small-cell lung cancer. J. Clin. Oncol. 40, 586\u2013597.","DOI":"10.1200\/JCO.21.01497"},{"key":"10.1016\/j.intimp.2025.115695_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115695_bb0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0175","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115695_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314728","article-title":"The enigmatic nature of the TCR-pMHC interaction: implications for CAR-T and TCR-T engineering","volume":"23","author":"Shevyrev","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115695_bb0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges","volume":"11","author":"Pang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0190","first-page":"663","article-title":"The recent advancement of TCR-T cell therapies for cancer treatment","volume":"56","author":"Zhao","year":"2024","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"key":"10.1016\/j.intimp.2025.115695_bb0195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative armoring of CAR and TCR T cells by T cell-restricted IL15 and IL21 universally enhances solid tumor efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0200","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115695_bb0205","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115695_bb0210","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2025.115695_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1229540","article-title":"How can cytokine-induced killer cells overcome CAR-T cell limits","volume":"14","author":"Cappuzzello","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115695_bb0220","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115695_bb0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaut.2017.06.008","article-title":"CIK as therapeutic agents against tumors","volume":"85","author":"Introna","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2025.115695_bb0230","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115695_bb0235","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115695_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115695_bb0245","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115695_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115695_bb0255","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-017-2061-4","article-title":"Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease","volume":"67","author":"Diem","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2025.115695_bb0260","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115695_bb0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115695_bb0270","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/2326-6066.CIR-18-0888","article-title":"Adoptive immunotherapy with antigen-specific T cells expressing a native TCR","volume":"7","author":"Leung","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0275","doi-asserted-by":"crossref","unstructured":"Ribas, A. & Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 213, 2835\u20132840.","DOI":"10.1084\/jem.20161462"},{"key":"10.1016\/j.intimp.2025.115695_bb0280","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.eururo.2018.11.002","article-title":"PD-L1 antibody comparison in urothelial carcinoma","volume":"75","author":"Rijnders","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2025.115695_bb0285","doi-asserted-by":"crossref","unstructured":"Kortekaas, K.E., et al. CD39 identifies the CD4+ tumor-specific T-cell population in human cancer. Cancer Immunol. Res. 8, 1311\u20131321.","DOI":"10.1158\/2326-6066.CIR-20-0270"},{"key":"10.1016\/j.intimp.2025.115695_bb0290","doi-asserted-by":"crossref","unstructured":"Savas, P., et al. Single-cell profiling of breast cancer T cells reveals a tissue-reside nt memory subset associated with improved prognosis. Nat. Med. 24, 986\u2013993.","DOI":"10.1038\/s41591-018-0078-7"},{"key":"10.1016\/j.intimp.2025.115695_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115695_bb0300","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-022-04839-2","article-title":"Deciphering the immunopeptidome in vivo reveals new tumour antigens","volume":"607","author":"Jaeger","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115695_bb0305","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy","volume":"615","author":"Puig-Saus","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115695_bb0310","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007180","article-title":"Single-cell sequencing on CD8(+) TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer","volume":"11","author":"Komuro","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.115695_bb0315","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2326-6066.CIR-19-0574","article-title":"CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy","volume":"8","author":"Kagamu","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-003-0473-9","article-title":"Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination","volume":"53","author":"Romero","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2025.115695_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.12.011","article-title":"Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies","volume":"42","author":"Goddard","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115695_bb0330","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115695_bb0335","article-title":"Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells","volume":"33","author":"Ma","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.intimp.2025.115695_bb0340","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"issue":"12","key":"10.1016\/j.intimp.2025.115695_bb0345","doi-asserted-by":"crossref","first-page":"105511","DOI":"10.1016\/j.isci.2022.105511","article-title":"Across-cancer immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis","volume":"25","author":"Diao","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2025.115695_bb0350","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1023\/A:1020452531828","article-title":"Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro","volume":"19","author":"Lutsiak","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.intimp.2025.115695_bb0355","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115695_bb0360","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115695_bb0365","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/path.5406","article-title":"The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice","volume":"250","author":"Gonzalez-Ericsson","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2025.115695_bb0370","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e8","article-title":"Peripheral blood immune cell-based biomarkers in anti-PD-1\/PD-L1 therapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2025.115695_bb0375","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.38","article-title":"Immunotherapy: antitumour T cells as peripheral biomarkers","volume":"13","author":"Hutchinson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115695_bb0380","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115695_bb0385","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115695_bb0390","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:32:24Z","timestamp":1765456344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925016868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"alternative-id":["S1567576925016868"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115695","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new T cell therapy method for cancer: polyclonal effector tumor antigen-specific T cells isolated from autologous blood or lymph nodes by nanoparticles loading whole tumor antigens","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115695"}}